Natural tissue regeneration specialist Osteopore (ASX:OSX) is changing the way surgery is conducted globally, improving patient outcomes while working to reduce medical costs.
Osteopore’s new executive chairman Mark Leong says surgical specialists in Australia and globally are increasingly seeking to harness the body’s natural regenerative capabilities, rather than rely on artificial replacement parts or bone grafts, which have limitations that regenerative implants can overcome.
“With bone grafts there is potential for pain at the harvest site and your body may even absorb the graft with no regeneration,” Leong says.
“Permanent implants are non-biodegradable with reported instances of infections, post-surgical complications and are difficult to micro-adjust for a better fit during the medical procedure.”
Be the first to comment